Oral PPI is currently the main clinical treatment method for GERD. Although it can relieve the symptoms of most patients, it does not address underlying pathophysiologic changes such as transient lower esophageal sphincter relaxation, mucosal nerve paresthesia, cardia relaxation, and hiatal hernia; therefore, it cannot fundamentally solve the problem and requires long-term medication. Even so, about 20% of refractory patients do not respond to medication, and a significant proportion of patients do find it difficult to tolerate long-term use. Since 2000, foreign scholars began to study Stretta microradiofrequency technology for the treatment of GERD. Radiofrequency refers to the electromagnetic wave with a frequency from 300 KHz to 300 GHz. Tissue ablation and cutting can be carried out by utilizing the thermal effect generated by radiofrequency. Most medical radiofrequency uses frequencies from 200 to 750 KHz. Stretta is currently a radiofrequency instrument used for the treatment of GERD, with a frequency of 465 KHz. Stretta is an endoscopic radiofrequency technology approved by the Food and Drug Administration (FDA) for the treatment of GERD in 2000. In recent years, Stretta trace radiofrequency therapy has been promoted and applied worldwide. Clinical studies have proved that this technique is a minimally invasive, simple, safe, and effective treatment [1–7].